Jana Prausová

7.2k total citations · 4 hit papers
54 papers, 4.1k citations indexed

About

Jana Prausová is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Hepatology. According to data from OpenAlex, Jana Prausová has authored 54 papers receiving a total of 4.1k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Oncology, 28 papers in Pulmonary and Respiratory Medicine and 9 papers in Hepatology. Recurrent topics in Jana Prausová's work include Colorectal Cancer Treatments and Studies (30 papers), Cancer Treatment and Pharmacology (17 papers) and Gastric Cancer Management and Outcomes (15 papers). Jana Prausová is often cited by papers focused on Colorectal Cancer Treatments and Studies (30 papers), Cancer Treatment and Pharmacology (17 papers) and Gastric Cancer Management and Outcomes (15 papers). Jana Prausová collaborates with scholars based in Czechia, Spain and United States. Jana Prausová's co-authors include Eric Van Cutsem, Josep Tabernero, Vladimir Moiseyenko, Radek Lakomý, Paul Ruff, David Ferry, Carmen J. Allegra, Guy A. Van Hazel, Teresa Macarulla and Joe McKendrick and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and The Lancet Oncology.

In The Last Decade

Jana Prausová

49 papers receiving 4.0k citations

Hit Papers

4 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen

2012 986 citations Eric Van Cutsem, Josep Tabernero et al. Journal of Clinical Oncology profile →
Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma

2011 877 citations Jana Prausová et al. Journal of Clinical Oncology profile →
EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer

2008 726 citations Jana Prausová et al. Journal of Clinical Oncology profile →
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study

2015 652 citations Josep Tabernero, Takayuki Yoshino et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jana Prausová Czechia	18	3.4k	1.5k	799	684	577	54	4.1k
Do Hoon Lim South Korea	34	1.5k 0.4×	2.8k 1.9×	854 1.1×	376 0.5×	395 0.7×	206	5.1k
Karen Borgonovo Italy	33	2.7k 0.8×	1.5k 1.0×	256 0.3×	545 0.8×	618 1.1×	83	3.8k
Roberto Petrioli Italy	28	1.6k 0.5×	1.2k 0.8×	124 0.2×	508 0.7×	330 0.6×	135	3.1k
Barry C. Lembersky United States	31	2.5k 0.7×	764 0.5×	115 0.1×	276 0.4×	555 1.0×	82	3.3k
Wei‐Xiang Qi China	24	1.1k 0.3×	940 0.6×	142 0.2×	426 0.6×	153 0.3×	109	2.1k
Shaodong Hong China	28	2.9k 0.8×	1.8k 1.2×	161 0.2×	619 0.9×	307 0.5×	128	3.9k
G. Seipelt Germany	26	1.6k 0.5×	1.2k 0.8×	204 0.3×	352 0.5×	611 1.1×	75	3.0k
Giacomo Cartenì Italy	27	1.7k 0.5×	1.4k 1.0×	277 0.3×	648 0.9×	213 0.4×	110	3.2k
Ullrich Graeven Germany	34	2.9k 0.9×	1.1k 0.7×	397 0.5×	974 1.4×	747 1.3×	135	4.4k
Vincenzo Adamo Italy	27	2.4k 0.7×	2.2k 1.5×	105 0.1×	1.0k 1.5×	246 0.4×	118	3.8k

Countries citing papers authored by Jana Prausová

Since Specialization

Citations

This map shows the geographic impact of Jana Prausová's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jana Prausová with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jana Prausová more than expected).

Fields of papers citing papers by Jana Prausová

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jana Prausová. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jana Prausová. The network helps show where Jana Prausová may publish in the future.

Co-authorship network of co-authors of Jana Prausová

This figure shows the co-authorship network connecting the top 25 collaborators of Jana Prausová. A scholar is included among the top collaborators of Jana Prausová based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jana Prausová. Jana Prausová is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kubeš, Jiří, et al.. (2021). Ultrahypofractionated Proton Radiation Therapy in the Treatment of Low and Intermediate-Risk Prostate Cancer-5-Year Outcomes. International Journal of Radiation Oncology*Biology*Physics. 110(4). 1090–1097. 10 indexed citations

Novakova-Jiresova, Alena, Kateřina Kopečková, Ludmila Boublíková, et al.. (2020). <p>Regorafenib for Metastatic Colorectal Cancer: An Analysis of a Registry-Based Cohort of 555 Patients</p>. Cancer Management and Research. Volume 12. 5365–5372. 9 indexed citations

Novakova-Jiresova, Alena, Kateřina Kopečková, Ludmila Boublíková, et al.. (2020). Regorafenib for Metastatic Colorectal Cancer: An Analysis of a Registry-Based Cohort of 555 Patients. SHILAP Revista de lepidopterología. 1 indexed citations

Vaňásek, J, Martin Doležel, Ladislav Dušek, et al.. (2020). Association of triple positivity with prognostic parameters and overall survival in a population-based study of 6,122 HER2-positive breast cancer patients: analysis of real-world clinical practice based on a research database. Neoplasma. 67(6). 1373–1383. 3 indexed citations

Cutsem, Eric Van, Bohuslav Melichar, Marc Van den Eynde, et al.. (2019). Phase 2 study results of murlentamab, a monoclonal antibody targeting the Anti-Mullerian-Hormone-Receptor II (AMHRII), acting through Tumor-Associated Macrophage engagement in advanced/metastatic colorectal cancers. Annals of Oncology. 30. iv153–iv154. 5 indexed citations

Rho, Young Soo, Marine Gilabert, Karol Połom, et al.. (2017). Comparing Clinical Characteristics and Outcomes of Young-onset and Late-onset Colorectal Cancer: An International Collaborative Study. Clinical Colorectal Cancer. 16(4). 334–342. 54 indexed citations

Büchler, Tomáš, Zbyněk Bortlíček, Karel Hejduk, et al.. (2016). P-153 Regorafenib in the real-life clinical practice: data from the czech registry. Annals of Oncology. 27. ii45–ii45.

Lonardi, Sara, Takayuki Yoshino, Radka Obermannová, et al.. (2016). Exposure-response (E-R) relationship of Ramucirumab (RAM) from a global, randomized, double-blind, Phase 3 study of patients (Pts) with advanced 2nd line colorectal cancer. Annals of Oncology. 27. iv40–iv40. 1 indexed citations

Kopečková, Kateřina, Tomáš Büchler, Zbyněk Bortlíček, et al.. (2016). Regorafenib in the Real-Life Clinical Practice: Data from the Czech Registry. Targeted Oncology. 12(1). 89–95. 18 indexed citations

10.

Bodoky, G., M. E. Scheulen, Fernando Rivera, et al.. (2015). Clinical Benefit and Health-Related Quality of Life Assessment in Patients Treated with Cisplatin/S-1 Versus Cisplatin/5-FU: Secondary End Point Results From the First-Line Advanced Gastric Cancer Study (FLAGS). Journal of Gastrointestinal Cancer. 46(2). 109–117. 15 indexed citations

11.

Kubáčková, Kateřina, Zbyněk Bortlíček, Tomáš Pavlík, et al.. (2014). Prognostic factors in renal cell carcinoma patients treated with sorafenib: results from the Czech registry. Targeted Oncology. 10(3). 385–392. 6 indexed citations

12.

Trédan, Olivier, Mario Campone, Jacek Jassem, et al.. (2014). Ixabepilone Alone or With Cetuximab as First-Line Treatment for Advanced/Metastatic Triple-Negative Breast Cancer. Clinical Breast Cancer. 15(1). 8–15. 49 indexed citations

13.

Ferry, David, Paul Ruff, Radek Lakomý, et al.. (2013). Time Course of Adverse Events in the Velour Trial. Annals of Oncology. 24. iv36–iv36. 1 indexed citations

14.

Ruff, Paul, David Ferry, Demetris Papamichael, et al.. (2013). Observed Benefit of Aflibercept in MCRC Patients ≥65 Years Old: Results of a Prespecified Age-Based Analysis of the Velour Study. Annals of Oncology. 24. iv18–iv18. 4 indexed citations

15.

Cutsem, Eric Van, Josep Tabernero, Radek Lakomý, et al.. (2012). Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen. Journal of Clinical Oncology. 30(28). 3499–3506. 986 indexed citations breakdown →

16.

Jarolím, L., Štěpán Veselý, Marek Babjuk, et al.. (2012). Časná salvage radioterapie po radikální prostatektomii indikovaná u pacientů s rostoucí hladinou PSA v hodnotách nižších, než je konvenční hranice biochemické recidivy 0,2 ng/ml. 16(2). 92–100.

17.

Boer, Richard de, Michael Clemens, Dusan Kotasek, et al.. (2010). Phase I/II randomised study of a novel erythropoiesis-stimulating agent (AMG 114) for the treatment of anaemia with concomitant chemotherapy in patients with non-myeloid malignancies. Medical Oncology. 28(4). 1210–1217. 2 indexed citations

18.

Rožková, Daniela, Jitka Fučíková, Jan Lašťovička, et al.. (2009). FOCUS on FOCIS: Combined chemo-immunotherapy for the treatment of hormone-refractory metastatic prostate cancer. Clinical Immunology. 131(1). 1–10. 28 indexed citations

19.

Charvát, J, et al.. (2006). Implantation of central venous ports with catheter insertion via the right internal jugular vein in oncology patients—single center experience. Supportive Care in Cancer. 14(11). 1162–1165. 55 indexed citations

20.

Österborg, Anders, Dusan Kotasek, Jana Prausová, et al.. (2006). A novel erythropoiesis-stimulating agent (AMG114) with 131-hour half-life effectively treats chemotherapy-induced anemia when administered as 200 mcg every 3 weeks. Journal of Clinical Oncology. 24(18_suppl). 8626–8626. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact